Mubritinib (TAK-165) is a potent and selective small molecule inhibitor targeting the HER2/ErbB2 tyrosine kinase, demonstrating an IC50 of 6 nM. It has been utilized in preclinical research to investigate HER2-driven cancers, showing antitumor activity in both cellular assays and in vivo xenograft models.